Exp Biol Med:新型药物递送系统靶向杀灭癌细胞,把化疗副作用降到很低!

2017-04-21 佚名 来宝网

发表在实验生物学和医学(第 242 卷,第 7 期,2017 年 3 月)的文章描述了一种用于治疗癌症的新药物递送系统。由凯斯西储大学生物医学工程系的 Horst A. von Recum 博士领导的研究报告指出,由肿瘤周围的酸性环境激活的植入式局部递送系统可提供持续的药物释放并不损伤健康组织。癌症护理的临床标准通常要求患者静脉注射药物。这种给药途径允许药物分布在患者的整个身体中,包括正常的组织。

发表在实验生物学和医学(第 242 卷,第 7 期,2017 年 3 月)的文章描述了一种用于治疗癌症的新药物递送系统。由凯斯西储大学生物医学工程系的 Horst A. von Recum 博士领导的研究报告指出,由肿瘤周围的酸性环境激活的植入式局部递送系统可提供持续的药物释放并不损伤健康组织。

癌症护理的临床标准通常要求患者静脉注射药物。这种给药途径允许药物分布在患者的整个身体中,包括正常的组织。在某些情况下,必须减少给药量和患者接受药物的时间,以防止损害正常组织。然而,这也减少了被杀死的癌细胞的数量。事实上,一些非常有效的癌症药物由于对正常组织有毒性而不能使用。例如,对大量肿瘤有效的多柔比星对肿瘤周围的心脏,肝脏,肾脏和健康组织有毒性。替代药物递送系统可以减少对正常组织的损伤,而不降低药物有效性,将改善许多癌症患者的临床治疗结果。

几项研究表明,pH 敏感递送系统可以克服与多柔比星治疗相关的毒性。然而,大多数这些系统不能满足杀死肿瘤细胞所必需的持续释放的要求。在这项研究中,von Recum 博士及其同事报道,在恶性肿瘤周围的微酸性环境中活化的多柔比星修饰形式能够在肿瘤部位优先释放多柔比星 40 天。活性药物可忽略的释放发生在健康组织周围的中性环境中。此外,该修饰形式的多柔比星的有效性等同于未修饰的药物。该系统能够比其他 pH 敏感的多柔比星递送系统递送药物的时间更长(10X),可以转化为较少的剂量。von Recum 博士说:“我们觉得这是一种很好的抗癌药物,因为总剂量远远低于全身使用的剂量,远低于心脏的毒性阈值。”

实验生物学和医学主编 Steven R.Goodman 博士说:“Recum 及其同事提供了一种 pH 敏感的 DOX 传递系统,其允许以特定于肿瘤组织的缓慢和稳定的速率递送药物。下一步将是进行动物试验。

原始出处:

Erika L Cyphert, Andrew S Fu, Horst A von Recum.Featured Article: Chemotherapeutic delivery using pH-responsive, affinity-based release.Exp Biol Med (Maywood). 2017 Apr

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-12-30 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-27 大爰

    学习新技术!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
    2017-04-23 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1917449, encodeId=be38191e44922, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 30 23:04:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824231, encodeId=dfb9182423147, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Aug 09 03:04:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767101, encodeId=3f201e67101d6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 12 01:04:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191045, encodeId=773b19104590, content=学习新技术!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Apr 27 09:34:48 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252228, encodeId=d230125222800, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486354, encodeId=68081486354f4, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568550, encodeId=53691568550d4, content=<a href='/topic/show?id=838794862d0' target=_blank style='color:#2F92EE;'>#递送系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94862, encryptionId=838794862d0, topicName=递送系统)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68f115392320, createdName=lingaifan, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607420, encodeId=e0be160e42075, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 23 04:04:00 CST 2017, time=2017-04-23, status=1, ipAttribution=)]

相关资讯

njp&#1602D&#160MA:利用2D纳米孔检测DNA甲基化&#160新型癌症诊断技术有望被开发

图片来源:www.sciencedaily.com 2017年4月18日 讯 /生物谷BIOON/ --对癌症进行早期检测,就好像DNA中所发生的改变,或许能够帮助增强研究人员对癌症的诊断和疗法的进行,同时还能够帮助理解疾病的发病机制,日前,一项刊登在国际杂志npj 2D Materials and applications上的研究报告中,来自伊利诺伊大学的研究人员通过研究开发了一种新方

“神药”雷帕霉素在治疗人类多种疾病上到底有多神?

雷帕霉素是一种新型大环内酯类免疫抑制剂,其是从一种生存在拉帕努伊岛上的细菌中分离出来的,最早期被研究作为低毒性的抗真菌药物,1977年研究人员发现雷帕霉素具有免疫抑制作用,1989年开始把雷帕霉素作为治疗器官移植的排斥反应的新药进行试用。 如今随着科学家们对雷帕霉素研究的深入,他们发现这种药物还具有其它多种用途,早在2009年,研究者就发现雷帕霉素可延长雌性小鼠的寿命约15%;同时还

Nature:对抗癌细胞自我复制的分子奥秘

近期来自杜克大学的一组研究人员模拟了生物分子的复杂形状和运动,描述了核苷类似物和天然核苷如何转运到细胞中的过程,他们发现这一系统的核心是一种特殊的分子:CNT(concentrative nucleoside transporter),从研究人员提供的动画中可以看到,CNT就像一部电梯一样慢慢的移动“货物”,停在跨细胞膜的各个点上,然后到达另一边。针对病毒感染和癌症最有效的治疗方法之一就是一类被称

研究发现新疗法,抗击癌症更有效!

在对抗癌症的战争中,强大的化疗药物越来越多地与免疫治疗组合在一起,为患者提供了更好的治疗方案以增强免疫系统,战胜癌症。

国家癌症中心:我国癌症新发人数占世界新发癌症病例的1/4

每年的4月15号至21号是肿瘤防治宣传周,今年宣传周的主题是“科学抗癌 关爱生命”。国家癌症中心发布的中国最新癌症数据显示,我国癌症新发人数在持续上升,增幅达3%,占世界新发癌症病例的1/4。从我国347家癌症登记中心的数据来看,我国居民在40岁之前,发病率处于较低水平,之后开始快速升高,80岁年龄组达到峰值。总体来说,我国肿瘤大病率在270/10万人口,我国的肿瘤的诊断和治疗水平上与国际先进水平

NATURE:科学家找到了癌细胞伪装的真相,或能将其一举歼灭

我们的免疫系统可以治愈癌症,这个问题听起来简单得让人不敢相信,可这就是新兴的癌症治疗法—免疫疗法的基础所在。来自蒙特利大学生物研究所的研究人员们发表了关于这一领域的新文章。